Do children with intermediate-risk Burkitt lymphoma benefit from adding rituximab?

The answer is yes. The randomization to addition of Rituximab in the recently closed international study was done in intermediate risk patients with high LDH (Minard-Colin et al., PMID 32492302) The trial was stopped early because of the clear advantage in the Rituximab arm. The only patients not st...

Just to clarify, Group B patients with normal LDH were not included in the randomized trial as they have a 95% EFS without rituximab.